Worst performer was SBTX:SkinBioTherapeutics, plunging 16% as more of the convertible loan was converted and flogged off. The share price is utterly screwed until that is paid off, and it could easily end up killing the company. Very distressing that I recently sunk £5,000 into this disaster. The only slim ray of hope is that a Croda deal is announced soon, as nothing else will save it.
OPTI:Optibiotix lost nearly all last week's gains, dropping 14% and causing a lot of the damage. I thought this time it may hold in the high 20's, but no such luck. I only hope that this is market makers forcing down the price to get some shares because they know an update of microbiome modulators is coming and figure that will make people want to buy.
RIO:Rio Tinto had a bad week, dropping 5% and after looking like they were about to get back into profit are now 18% down.
Better news for JLP:Jubilee Metals, with a 6% increase hopefully meaning they have reached their bottom. News on confirming the deal with IRH should help boost the price.
PAF:Pan African Resources has been progressing steadily, helped by the rise in gold price, and went up 7% this week so both my holdings are well in profit.
EDV:Endeavour Mining has been hammered lately, but went up 10% this week and is now 27% down.
Share of the Week is my other gold producer CEY:Centamin, which climbed 11% and is only 4% down now. Fortunately I doubled my holding before the price went up, a rare example of good timing.
Here's the ISA and shares portfolio after week 32 of year 9.
| Weekly Change | |||
| Cash | £69.28 | -£3.75 | |
| Portfolio cost | £99,231.92 | +£0 | |
| Portfolio sell value (bid price-commission) |
£46,423.47 | (-53.2%) | -£4,447.49 |
| Potential profits | £1,739.41 | -£792.76 | |
| Yr 9 Dividends | £215.92 | +£0 | |
| Yr 9 Interest | £3.71 | +£0 | |
| Yr 9 Profit from sales | £11.13 | +£0 | |
| Yr 9 proj avg monthly profit | £24.04 | (0.4%) | -£1.30 |
| Total Dividends | £12,127.35 | +£0 | |
| Total Interest | £5.64 | +£0 | |
| Total Profit from sales | £17,309.66 | +£0 | |
| Average monthly cash profit | £280.61 | (4.8%) | -£0.67 |
|
(Sold stocks profit + Dividends - Fees / Months) |
|||
| Compound performance | 41% | +0% |
Huge drop mostly thanks to OPTI:Optibiotix and SBTX:SkinBioTherapeutics. My cheapest holding of OPTI is the only profitable share, so potential profits were hammered by £792. Monthly fees slightly reduced cash.
It appears last week's rise was a blip.
Back to being well below the trend line.
The SIPP looks like this after week 432 overall and week 16 of year 9.
| Weekly Change | ||||
| Cash | £372.71 | +£260.98 | ||
| Portfolio cost | £106,886.06 | +£2,072.36 | ||
| Portfolio sell value (bid price - commission) | £58,122.99 | (-45.6%) | -£3,599.25 | |
| Potential profits | £1,248.68 | +£227.25 | ||
| Yr 9 Dividends | £173.88 | +£0 | ||
| Yr 9 Interest | £1.24 | +£0 | ||
| Yr 9 Profit from sales | £3,373.97 | +£0 | ||
| Yr 9 proj avg monthly profit | £941.76 | (15.8%) | -£67.60 | |
| Total Dividends | £14,808.76 | +£0 | ||
| Total Interest | £7.17 | +£0 | ||
| Total Profit from sales | £14,209.87 | +£0 | ||
| Average monthly cash profit | £278.82 | (4.7%) | -£0.82 | |
| (Sold stocks profit + Dividends - Fees / Months) | ||||
| Compound performance | 39% | -1% |
Added my monthly £250 savings to cash. Also my pension transfer of £2,100 came through and I used it to buy 1,007 shares in CEY:Centamin at 99.214p costing £1,011.03. They ended the week at 103.5p bid price which was nice. The other half was spent on 675 shares of CAML:Central Asia Metals at 155.4632p costing £1,061.33.
Share value was hammered in the same way as the ISA, but none of my OPTI:Optibiotix holdings are in profit, so potential profit actually rose by £227 mainly thanks to gold mines.
Drop is less steep thanks to cash injection.
No hiding the drop on this chart.
The trading account looks like this after week 398 overall and week 34 of year 8.
Although both BARC:Barclays and JLP:Jubilee Metals had decent gains this week, the collapse in SBTX:SkinBioTherapeutics wiped most of that out and the value went up by just 13p. BARC:Barclays is £18 in potential profit and I have dividends too, so not long before I think about selling them.
Below where we were 8 months ago but creeping upwards
Reluctant to cross the trend line
A week late writing this as I was in the Lake District, so will save any thoughts for the next edition which I need to write later today, but the rain has stopped so it's time to hit the allotment!
Drop is less steep thanks to cash injection.
No hiding the drop on this chart.
The trading account looks like this after week 398 overall and week 34 of year 8.
| Weekly Change | |||
| Cash | £0.07 | +£0 | |
| Portfolio cost | £2,076.23 | +£0 | |
| Portfolio sell value (bid price - commission) | £1,249.13 | (-39.8%) | +£0.13 |
| Potential profits | £18.30 | +£7.92 | |
| Year 8 Dividends | £8.56 | +£0 | |
| Year 8 Interest | £0 | +£0 | |
| Year 8 Profit | £283.99 | +£0 | |
| Yr 8 proj avg monthly profit | £37.29 | (+21.5%) | -£1.13 |
| Dividends | £68.66 | +£0 | |
| Interest | £0.03 | +£0 | |
| Profit from sales | -£646.70 | +£0 | |
| Average monthly cash profit | -£6.29 | (-3.6%) | +£0.02 |
| (Sold stocks profit + Dividends - Fees / Months) |
Although both BARC:Barclays and JLP:Jubilee Metals had decent gains this week, the collapse in SBTX:SkinBioTherapeutics wiped most of that out and the value went up by just 13p. BARC:Barclays is £18 in potential profit and I have dividends too, so not long before I think about selling them.
Below where we were 8 months ago but creeping upwards
Reluctant to cross the trend line
A week late writing this as I was in the Lake District, so will save any thoughts for the next edition which I need to write later today, but the rain has stopped so it's time to hit the allotment!
No comments:
Post a Comment